menu

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer

    FDA oncologists discuss niraparib for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    • Overview

      FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

      Released May 18, 2017

    Facebook Comments

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.